DOCSLIB.ORG

Patent Application Publication ( 10 ) Pub . No . : US 2019 / 0169224 A1

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Patent Application Publication ( 10 ) Pub . No . : US 2019 / 0169224 A1 US 20190169224A1 ( 19) United States (12 ) Patent Application Publication (10 ) Pub. No. : US 2019 /0169224 A1 CAVANAGH et al. (43 ) Pub . Date : Jun . 6 . 2019 ( 54 ) PREPARATIONS OF HYDROPHOBIC 487, filed on Aug. 23 , 2012 , provisional application THERAPEUTIC AGENTS , METHODS OF No . 61 /763 ,770 , filed on Feb . 12 , 2013 , provisional MANUFACTURE AND USE THEREOF application No . 61/ 788 ,519 , filed on Mar. 15 , 2013 . (71 ) Applicant: NICOX OPHTHALMICS, INC. , Fort Worth , TX (US ) Publication Classification ( 72 ) Inventors : Thomas CAVANAGH , New Canaan , (51 ) Int. CI. CT (US ) ; Shikha P . Barman , Bedford , C07 ) 7700 (2006 . 01) MA (US ) ; Tian Hao , Acton , MA (US ) ; C07 ) 71 /00 ( 2006 . 01 ) Thomas B . Leland, Bolton , MA (US ) ; C07J 3 /00 ( 2006 .01 ) Ritesh V . Thekkedath , Dombivli ( E ) . C07 ) 31 /00 (2006 . 01) M . S . ( IN ) (52 ) U . S . CI. CPC C07J 77009 ( 2013 .01 ) ; C07J 71 /0031 ( 2013 . 01 ) ; C07J 3 /005 ( 2013 .01 ) ; Y10T ( 21 ) Appl. No. : 16 / 203, 324 428 / 2982 (2015 . 01 ) ; C07J 71/ 0005 ( 2013 .01 ) ; ( 22 ) Filed : Nov . 28 , 2018 CO7B 2200 /13 ( 2013. 01 ) ; C07J 31/ 006 Related U . S . Application Data ( 2013 .01 ) (63 ) Continuation of application No. 15 / 660 ,470 , filed on (57 ) ABSTRACT Jul. 26 , 2017 , now Pat. No . 10 , 174 ,071 , which is a continuation of application No . 14 /399 ,780 , filed on The present invention further provides method of preparing Nov . 7 , 2014 , now Pat . No . 9 , 822, 142, filed as appli nanocrystals of a hydrophobic therapeutic agent such as cation No . PCT/ US2013 /039694 on May 6 , 2013 , fluticasone or triamcinolone , pharmaceutical compositions which is a continuation of application No . 13 / 735 , ( e . g ., topical or intranasal compositions ) thereof and meth 973 , filed on Jan . 7 , 2013 , now Pat. No . 8 , 765 ,725 . ods for treating and / or preventing the signs and / or symptoms (60 ) Provisional application No . 61/ 644 , 105 , filed on May of disorders such as blepharitis , meibomian gland dysfunc 8 , 2012 , provisional application No . 61 /657 ,239 , filed tion or skin inflammation or a respiratory disease ( e . g . , on Jun . 8 , 2012 , provisional application No . 61 /692 , asthma) . Patent Application Publication Jun . 6 , 2019 Sheet 1 of 42 US 2019 / 0169224 A1 . : . 2 . ChemicalStructureofFluticasonePropionate FIG.1 w wwwwwwwwwwwwww .. : Physico-ChemicalCharacteristicsofFluticasonePropionate : 272-273C(DSC/TGA) afterrightDecomposes 7. 7 500.57Daltons : |240nm 14.48 melting NO IandII Case * * * * * * EL * * * * * * * * * * * ATA : : S KINYARWANA VIEWS MeltingPoint PointDecompositionAAA Polymorphicforms MolecularFormula ???? d60 Properties APlimax M.W pka Photolabile Patent Application Publication Jun . 6 , 2019 Sheet 2 of 42 US 2019 / 0169224 A1 Impurity 12min 11 Impurity 10 eerecer Baselineexpansionofimpurities ranv rei 199.63 9 16.80450098 35.56320:21 *.PASAP 17070. FluticasonePropionateanditsimpuritiesB,CD Impurity mesmo menit u n pocoRin * * whommes h wit . MAU Y 2.FIG 15min .66 0.72 ht ., . .???????????????????????????????????????- 14 1 . 0 13 . .2 8 12 10.4 14. 59. 4 11 HPLCofFluticasonePropionateanditsimpurities 99?."??????07???????>?????????,????????- 10 9 De FPS 8 7 . N O . 2 . 1 . - - . AN . 1 MAU 700 Patent Application Publication Jun . 6 , 2019 Sheet 3 of 42 US 2019 / 0169224 A1 FilingLine Addfinalexcipienis(optional) i ? conc.desiredconcentrateto1933 TangentialFlow NY Purify,addvehicleand . LE FIG.3 febrero (BatchProcess)0000000 Undersecondtemp.,e25°C PhaseII) PhaseIII Erse (Phase 00 Soose min/mi.41-50:rateowH Stenle-filtered Underfirsttemp.,294°C X Generationofnano-crystals 74 % DissolveFPandsterilefilter fpDissolved insterile SVILES w XXXX Patent Application Publication Jun . 6 , 2019 Sheet 4 of 42 US 2019 / 0169224 A1 Addotherexcipients(optional) FillingLinew Por. D W WHAT AW :. x codes Xu MW Rui (8.9,TFForhollowfibercartridge) WON PurificationApparatus ** * CE N 20 - 5 FIG.4 Annealing/HoldTank Undersecondtemp.,6925°C ProcessofNanocrystalProductionandPurification CAD OUT Underfirsttemp. * TI ter 99 % Stenle PATRODAL Patent Application Publication Jun . 6 , 2019 Sheet 5 01of 4242 US 2019 / 0169224 A1 1.' 0.512405913 . )cp15 (MC %25 .A0 /BAK %12 .0 2.91 )cp15 ( MC %25 .0/ BAK %12 .0 X) cm15 ( MC %25 .0 /BAK %12 .0 1.376XD ...% 50 . 0 /PVA %70 .0/ BAKourth Att %13 .0 Tema146 water/)cp 4000 (HPMC %51. 0 /BAK %15 .0 0.641418631 * * * * Water/Tween80 % 86 .1/ PVA %38 .1 doooos Frie water/CMC %5. 0/ 80 Tween %2 FIG.5 water/CMC %5 .0/ Tween80 %2 *water /CMC %5 .0/ 80 Tween %2 ParticlesizeofFPnanocrystalbatches 1113 H * * * * waterwater/CMC/ Gum %9Xanthan. 0/ 80 Tween% 5. 0/ 80 % 2 Tween % 2 soooooo * * ** * water/CMC %9 .0/ 80 Tween %2 Water/CMCBAK %%365 ..01 / Tween60 %9 .0 water/Tween20 %58 .0 water/Tween20 a% 8. 0 microns in Size Patent Application Publication Jun . 6 , 2019 Sheet 6 of 42 US 2019 / 0169224 A1 * . ooo risurrecce . ** * 1992. SYA WN 5000 . * * * AW 9 : 00 * 2. ** CA * V . AVXXXXX YENT XXX LUX IVACY w 123456789101112131415161718192021222324252627282930 Particlesizeofbatchesobtainedby“top-down"particle2 BATCH# FIG.6 reductiontechniques Microfluidization $Ultrasound uopjezusiowohu OS 7 :17 2ML . * 940002 1 CAPSO 25 8 39 Scott ??? Patent Application Publication Jun . 6 , 2019 Sheet 7 of 42 US 2019 / 0169224 A1 ;2. i i 277.vrrrrrrr . E.L T +7/111 . S 6.5/006%FP 11 " . 117411122 rriii 22 . 2 wir : oots % 0.25%MC/12BAK,PH * .55FFEE i DJ/ VW b& * + 1 . 22 po . 1 :.III 360Bongo . Rrrrr!.1177rrmVrrrrrrr- FIG.7 ww . 5./01%FP . W r . EffectofpHonparticlesize ilF.FE M 22 rirrrrrrr.'-rrrrrrrr1 rrrrrrrr. rururawrrrrrrrrrrrrrrrrrrrr EE . T . T : . -2222, - #xILLIOZY Phosphate0.1%/25 MC10.12%BAK,PH7/01 .-11222222222 CY 122222.:-222222222 1222271:27 rerirrrrrrrrrrrrrrr Hécrittrrrrrr Patent Application Publication Jun . 6 , 2019 Sheet 8 of 42 US 2019 / 0169224 A1 SYYYSYLLTY : . : ' S ' YY 714 * * * * * )cp4000 (MC r+11877- . UFRIR /2142. )cp50 ( MC ! Frrr 177. 427 -. ????????? )cp15 (MC " ??????????????? FIG.8 .us EffectofstabilizerinphaseIIonparticlesize40 )cp45 ( HPMC ooooooo walan errrrr )cp000 , 100( HPMC st *** * * * vreerreen ? ? ?? ? ? ? ? ?- - - ???? ? ? ?? ??? ?????? . ? ? ? ? ? )cp4000 (HPMC $ $ 1999 )microns ( Size Particle Patent Application Publication Jun . 6 , 2019 Sheet 9 of 42 US 2019 / 0169224 A1 30 . X A NXXXXXX MUUTTOV* * * * * * * A LA2222222222222* XXXXXXXXXX 24124222223 * * T22WXXXXXXX* * * * * * * * * * * * * * * 2 1922 * 22222 XLIXL2411 22222222222222222222 . 111 22222 2 2222 LILL21222 , 3" LYWELYYYYYAX122X122X2 LLLLLLLLLLLLLL122222XXXXXX LL22 WAMWWW 11MNIA122 * 1423 1214224242424242242 . 2 * * 3 2323 err/4' 2 ALLY. MALESRh212121 irr-.777 522222222 YUYULA 2 22222 24 12. 2012. 2222222 22292 .44111117/7W Daysat25C FIG.9 2 2222222. 22 2 . 7 * L 012LLLLLLLL 1411172241222222222222012 022 2 1912922222222322 EffectofpHphaseIII(I+II)onparticlesize in1.2rrt' %pH7.5 2441442444919421211211 2X41421194LIKE1922- .? 242212. 2011 222222 * 49 , ' * ' * ' * * ' * ' YYN Y , 34 , 922399 , 99 * .-224/ V ILLE KAT T ' AKLA RE 24X14X 112 22 * * 24 * * * 4III PH5, .-22411 MLXLXX X* . 112 L110 1111111111 11111 . tum 2211. LLLLLLLLS 9222242 11 - 19 ELEO oped Patent Application Publication Jun . 6 , 2019 Sheet 10 of 42 US 2019 /0169224 A1 Batch2 46 14 VANVANKAw doo of 2 -._ PurifiedFluticasonePropionatenanoparticlesdonotdisplay 2345 particlesizegrowthovertime TimeinDays(25degreesC) FIG.10 oooooo 1 *.14 0 AZ CAT TiffSTRANI 900004 microns in Size Particle Patent Application Publication Jun . 6 , 2019 Sheet 11 of 42 US 2019 /0169224 A1 ULAWESI M FIG.12 * * 55F 17 ) d90( Size Particle . .ix .-', . .-' .: FIG.11 : '.- .,'Y: . 26CC .'-: .:;' : 2.80 ,.': '.-: : . : ) microns( Size Particle Patent Application Publication Jun . 6 , 2019 Sheet 12 of 42 US 2019 / 0169224 A1 44444444444444444444444444+. - ', . 14:.siirrr11rrrrrrrrterr+10-, . 2 . FIG.14 .4 Loss+777 Percent ?? TTTTTTTTTTTTTTTTTTTTTTIIIIIIIIIIIIIIIIIIIIIIIIIIIITTEETTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT KOLS FIG.13 WARWOUDERDORPODDARROLDANDO Patent Application Publication Jun . 6 , 2019 Sheet 13 of 42 US 2019 /0169224 A1 0005 Time(hours)attershaking FIG.16 DUHAYASSES ??????????????????? TEEEEE E EEEEEEEEE mrs ????????????????????? .' ????????? wowwwwwwastewwww*ewwwwwwww FIG.15 ???????????????????????????????????????? '. t Patent Application Publication Jun . 6 , 2019 Sheet 14 of 42 US 2019 /0169224 A1 * * * * * * * * * * * * *' . 1 * . * . + - . - - Hours Unr:7417711111/4icrrrr1111111*arrrrrr11142333resrrrid1144472377774684648x2rstmird'AWasy.1244477157714628444 . .- FIG.18 * reserwerowniamnuwe . www.err+* 12"117,112 WHWWU19 060 DOCX Golec13/Bust ??????????????????????????????? Andrews WFP sou AAN VersAV+$ Awards 5 - - 747* FIG.17 C-00211111Hittw1ddiesasswdirasaiwww 11111110V Patent Application Publication Jun . 6 , 2019 Sheet 15 of 42 US 2019 /0169224 A1 fonda 16 . 0275 + 13 .6625 A . 10 .8500 6 . 3500 . 2 . 5650 -- - 14 . 8750 FIG . 19 Patent Application Publication Jun . 6 , 2019 Sheet 16 of 42 US 2019 /0169224 A1 d90 ,Size Particle - . SV 24u.onc . -.enian -.811 nevr.reranian . 1 .nnu-v :-nr - Xogo * ? *. ?. r.- .? 17. 1 Whip - -??? -+ x - * -02.4comocarsrubrerriorea42onee 177 "A. Xo . 2: -renerver.ver:nonvr121vironunr20ronrrnuviscommenun . - - - >www ~r.cznenanros ara. - . 2 S Virk-Orterrrrr":479, .4 2 3 / . 1 reannutry.ove 1 2 .21 1 . W Frror- -11 50Lof0.2%NanosuspensionCanbeProducedin4h ?> FIG.20 : x .1 . Sirenitywar. 13.11 - - kr.orrunnbinrrerrtract4cdrreramordnnv-v rv29:~rry-1032.11> veror.oor)vnnonki-6onnen:roretrneinversrenr
Load more

Recommended publications
  • Nitrate Prodrugs Able to Release Nitric Oxide in a Controlled and Selective
    Europäisches Patentamt *EP001336602A1* (19) European Patent Office Office européen des brevets (11) EP 1 336 602 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.7: C07C 205/00, A61K 31/00 20.08.2003 Bulletin 2003/34 (21) Application number: 02425075.5 (22) Date of filing: 13.02.2002 (84) Designated Contracting States: (71) Applicant: Scaramuzzino, Giovanni AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU 20052 Monza (Milano) (IT) MC NL PT SE TR Designated Extension States: (72) Inventor: Scaramuzzino, Giovanni AL LT LV MK RO SI 20052 Monza (Milano) (IT) (54) Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases (57) New pharmaceutical compounds of general effects and for this reason they are useful for the prep- formula (I): F-(X)q where q is an integer from 1 to 5, pref- aration of medicines for prevention and treatment of in- erably 1; -F is chosen among drugs described in the text, flammatory, ischemic, degenerative and proliferative -X is chosen among 4 groups -M, -T, -V and -Y as de- diseases of musculoskeletal, tegumental, respiratory, scribed in the text. gastrointestinal, genito-urinary and central nervous sys- The compounds of general formula (I) are nitrate tems. prodrugs which can release nitric oxide in vivo in a con- trolled and selective way and without hypotensive side EP 1 336 602 A1 Printed by Jouve, 75001 PARIS (FR) EP 1 336 602 A1 Description [0001] The present invention relates to new nitrate prodrugs which can release nitric oxide in vivo in a controlled and selective way and without the side effects typical of nitrate vasodilators drugs.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2017/0152273 A1 Merchant Et Al
    US 20170152273A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2017/0152273 A1 Merchant et al. (43) Pub. Date: Jun. 1, 2017 (54) TOPCAL PHARMACEUTICAL Publication Classification FORMULATIONS FOR TREATING (51) Int. Cl. NFLAMMLATORY-RELATED CONDITIONS C07F 5/02 (2006.01) Applicant: A6II 47/06 (2006.01) (71) Anacor Pharmaceuticals Inc., New A69/06 (2006.01) York, NY (US) A6IR 9/00 (2006.01) (72) Inventors: Tejal Merchant, Cupertino, CA (US); A6II 47/8 (2006.01) Dina Jean Coronado, Danville, CA A6II 45/06 (2006.01) (US); Charles Edward Lee, Union A6II 47/10 (2006.01) City, CA (US); Delphine Caroline A6II 3/69 (2006.01) Imbert, Cupertino, CA (US); Sylvia (52) U.S. Cl. Zarela Yep, Milpitas, CA (US) CPC .............. C07F 5/025 (2013.01); A61K 47/10 (2013.01); A61K 47/06 (2013.01); A61K3I/69 (73) Assignee: Anacor Pharmaceuticals Inc., New (2013.01); A61K 9/0014 (2013.01); A61 K York, NY (US) 47/183 (2013.01); A61K 45/06 (2013.01); A61K 9/06 (2013.01); C07B 2.200/13 (21) Appl. No.: 15/364,347 (2013.01) (22) Filed: Nov. 30, 2016 (57) ABSTRACT Related U.S. Application Data (60) Provisional application No. 62/420,987, filed on Nov. Topical pharmaceutical formulations, and methods of treat 11, 2016, provisional application No. 62/260,716. ing inflammatory conditions with these formulations, are filed on Nov. 30, 2015. disclosed. Patent Application Publication Jun. 1, 2017. Sheet 1 of 4 US 2017/0152273 A1 ?zzzzzzzzzzzzzzzzzzzzzzzzzzzz ????????????????????????????????????????????????????????????????????? S&S&S Šx&N Sssssssssssssssssssssssssssssssssssssss (r) eqn. O. peppy jeeNA go eunO/A Patent Application Publication Jun.
    [Show full text]
  • Activity of Selected Group of Monoterpenes in Alzheimer's
    International Journal of Molecular Sciences Review Activity of Selected Group of Monoterpenes in Alzheimer’s Disease Symptoms in Experimental Model Studies—A Non-Systematic Review Karolina Wojtunik-Kulesza 1,*, Monika Rudkowska 2, Kamila Kasprzak-Drozd 1,* , Anna Oniszczuk 1 and Kinga Borowicz-Reutt 2 1 Department of Inorganic Chemistry, Medical University of Lublin, Chod´zki4a, 20-093 Lublin, Poland; [email protected] 2 Independent Experimental Neuropathophysiology Unit, Medical University of Lublin, Jaczewskiego 8b, 20-090 Lublin, Poland; [email protected] (M.R.); [email protected] (K.B.-R.) * Correspondence: [email protected] (K.W.-K.); [email protected] (K.K.-D.) Abstract: Alzheimer’s disease (AD) is the leading cause of dementia and cognitive function im- pairment. The multi-faced character of AD requires new drug solutions based on substances that incorporate a wide range of activities. Antioxidants, AChE/BChE inhibitors, BACE1, or anti-amyloid platelet aggregation substances are most desirable because they improve cognition with minimal side effects. Plant secondary metabolites, used in traditional medicine and pharmacy, are promising. Among these are the monoterpenes—low-molecular compounds with anti-inflammatory, antioxidant, Citation: Wojtunik-Kulesza, K.; enzyme inhibitory, analgesic, sedative, as well as other biological properties. The presented review Rudkowska, M.; Kasprzak-Drozd, K.; focuses on the pathophysiology of AD and a selected group of anti-neurodegenerative monoterpenes Oniszczuk, A.; Borowicz-Reutt, K. and monoterpenoids for which possible mechanisms of action have been explained. The main body Activity of Selected Group of of the article focuses on monoterpenes that have shown improved memory and learning, anxiolytic Monoterpenes in Alzheimer’s and sleep-regulating effects as determined by in vitro and in silico tests—followed by validation in Disease Symptoms in Experimental in vivo models.
    [Show full text]
  • Classification of Medicinal Drugs and Driving: Co-Ordination and Synthesis Report
    Project No. TREN-05-FP6TR-S07.61320-518404-DRUID DRUID Driving under the Influence of Drugs, Alcohol and Medicines Integrated Project 1.6. Sustainable Development, Global Change and Ecosystem 1.6.2: Sustainable Surface Transport 6th Framework Programme Deliverable 4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Due date of deliverable: 21.07.2011 Actual submission date: 21.07.2011 Revision date: 21.07.2011 Start date of project: 15.10.2006 Duration: 48 months Organisation name of lead contractor for this deliverable: UVA Revision 0.0 Project co-funded by the European Commission within the Sixth Framework Programme (2002-2006) Dissemination Level PU Public PP Restricted to other programme participants (including the Commission x Services) RE Restricted to a group specified by the consortium (including the Commission Services) CO Confidential, only for members of the consortium (including the Commission Services) DRUID 6th Framework Programme Deliverable D.4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Page 1 of 243 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Authors Trinidad Gómez-Talegón, Inmaculada Fierro, M. Carmen Del Río, F. Javier Álvarez (UVa, University of Valladolid, Spain) Partners - Silvia Ravera, Susana Monteiro, Han de Gier (RUGPha, University of Groningen, the Netherlands) - Gertrude Van der Linden, Sara-Ann Legrand, Kristof Pil, Alain Verstraete (UGent, Ghent University, Belgium) - Michel Mallaret, Charles Mercier-Guyon, Isabelle Mercier-Guyon (UGren, University of Grenoble, Centre Regional de Pharmacovigilance, France) - Katerina Touliou (CERT-HIT, Centre for Research and Technology Hellas, Greece) - Michael Hei βing (BASt, Bundesanstalt für Straßenwesen, Germany).
    [Show full text]
  • List of Union Reference Dates A
    Active substance name (INN) EU DLP BfArM / BAH DLP yearly PSUR 6-month-PSUR yearly PSUR bis DLP (List of Union PSUR Submission Reference Dates and Frequency (List of Union Frequency of Reference Dates and submission of Periodic Frequency of submission of Safety Update Reports, Periodic Safety Update 30 Nov. 2012) Reports, 30 Nov.
    [Show full text]
  • NINDS Custom Collection II
    ACACETIN ACEBUTOLOL HYDROCHLORIDE ACECLIDINE HYDROCHLORIDE ACEMETACIN ACETAMINOPHEN ACETAMINOSALOL ACETANILIDE ACETARSOL ACETAZOLAMIDE ACETOHYDROXAMIC ACID ACETRIAZOIC ACID ACETYL TYROSINE ETHYL ESTER ACETYLCARNITINE ACETYLCHOLINE ACETYLCYSTEINE ACETYLGLUCOSAMINE ACETYLGLUTAMIC ACID ACETYL-L-LEUCINE ACETYLPHENYLALANINE ACETYLSEROTONIN ACETYLTRYPTOPHAN ACEXAMIC ACID ACIVICIN ACLACINOMYCIN A1 ACONITINE ACRIFLAVINIUM HYDROCHLORIDE ACRISORCIN ACTINONIN ACYCLOVIR ADENOSINE PHOSPHATE ADENOSINE ADRENALINE BITARTRATE AESCULIN AJMALINE AKLAVINE HYDROCHLORIDE ALANYL-dl-LEUCINE ALANYL-dl-PHENYLALANINE ALAPROCLATE ALBENDAZOLE ALBUTEROL ALEXIDINE HYDROCHLORIDE ALLANTOIN ALLOPURINOL ALMOTRIPTAN ALOIN ALPRENOLOL ALTRETAMINE ALVERINE CITRATE AMANTADINE HYDROCHLORIDE AMBROXOL HYDROCHLORIDE AMCINONIDE AMIKACIN SULFATE AMILORIDE HYDROCHLORIDE 3-AMINOBENZAMIDE gamma-AMINOBUTYRIC ACID AMINOCAPROIC ACID N- (2-AMINOETHYL)-4-CHLOROBENZAMIDE (RO-16-6491) AMINOGLUTETHIMIDE AMINOHIPPURIC ACID AMINOHYDROXYBUTYRIC ACID AMINOLEVULINIC ACID HYDROCHLORIDE AMINOPHENAZONE 3-AMINOPROPANESULPHONIC ACID AMINOPYRIDINE 9-AMINO-1,2,3,4-TETRAHYDROACRIDINE HYDROCHLORIDE AMINOTHIAZOLE AMIODARONE HYDROCHLORIDE AMIPRILOSE AMITRIPTYLINE HYDROCHLORIDE AMLODIPINE BESYLATE AMODIAQUINE DIHYDROCHLORIDE AMOXEPINE AMOXICILLIN AMPICILLIN SODIUM AMPROLIUM AMRINONE AMYGDALIN ANABASAMINE HYDROCHLORIDE ANABASINE HYDROCHLORIDE ANCITABINE HYDROCHLORIDE ANDROSTERONE SODIUM SULFATE ANIRACETAM ANISINDIONE ANISODAMINE ANISOMYCIN ANTAZOLINE PHOSPHATE ANTHRALIN ANTIMYCIN A (A1 shown) ANTIPYRINE APHYLLIC
    [Show full text]
  • Download Supplementary
    Supplementary Materials: High throughput virtual screening to discover inhibitors of the main protease of the coronavirus SARS-CoV-2 Olujide O. Olubiyi1,2*, Maryam Olagunju1, Monika Keutmann1, Jennifer Loschwitz1,3, and Birgit Strodel1,3* 1 Institute of Biological Information Processing: Structural Biochemistry, Forschungszentrum Jülich, Jülich, Germany 2 Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Obafemi Awolowo University, Ile-Ife, Nigeria 3 Institute of Theoretical and Computational Chemistry, Heinrich Heine University Düsseldorf, 40225 Düsseldorf, Germany * Corresponding authors: [email protected], [email protected] List of Figures S1 Chemical fragments majorly featured in the top performing 9,515 synthetic com- pounds obtained from screening against the crystal structure of the SARS-CoV-2 main protease 3CLpro. .................................. 2 S2 Chemical fragments majorly featured in the top 2,102 synthetic compounds obtained from ensemble docking and application of cutoff values of ∆G ≤ −7.0 kcal/mol and ddyad ≤ 3.5 Å. ............................ 2 S3 The poses and 3CLpro–compound interactions of phthalocyanine and hypericin. 3 S4 The poses and 3CLpro–compound interactions of the four best non-FDA-approved and investigational drugs. ............................... 4 S5 The poses and 3CLpro–compound interactions of zeylanone and glabrolide. 5 List of Tables S1 Names and properties of the compounds binding best to the active site of 3CLpro. 6 1 Supporting Material: High throughput virtual screening for 3CLpro inhibitors Figure S1: Chemical fragments majorly featured in the top performing 9,515 synthetic com- pounds obtained from screening against the crystal structure of the SARS-CoV-2 main pro- tease 3CLpro. The numbers represent the occurrence in absolute numbers.
    [Show full text]
  • (19) United States (12) Patent Application Publication (10) Pub
    US 20050181041A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2005/0181041 A1 Goldman (43) Pub. Date: Aug. 18, 2005 (54) METHOD OF PREPARATION OF MIXED Related US. Application Data PHASE CO-CRYSTALS WITH ACTIVE AGENTS (60) Provisional application No. 60/528,232, ?led on Dec. 9, 2003. Provisional application No. 60/559,862, ?led (75) Inventor: David Goldman, Portland, CT (US) on Apr. 6, 2004. Correspondence Address: Publication Classi?cation LEYDIG VOIT & MAYER, LTD (51) Int. Cl.7 ....................... .. A61K 31/56; A61K 38/00; TWO PRUDENTIAL PLAZA, SUITE 4900 A61K 9/64 180 NORTH STETSON AVENUE (52) US. Cl. ............................ .. 424/456; 514/179; 514/2; CHICAGO, IL 60601-6780 (US) 514/221 (73) Assignee: MedCrystalForms, LLC, Hunt Valley, (57) ABSTRACT MD This invention pertains to a method of preparing mixed phase co-crystals of active agents With one or more materials (21) Appl. No.: 11/008,034 that alloWs the modi?cation of the active agent to a neW physical/crystal form With unique properties useful for the delivery of the active agent, as Well as compositions com (22) Filed: Dec. 9, 2004 prising the mixed phase co-crystals. Patent Application Publication Aug. 18, 2005 Sheet 1 0f 8 US 2005/0181041 A1 FIG. 1a 214.70°C z.m."m.n... 206.98°C n..0ao 142 OJ/g as:20m=3: -0.8 -1.0 40 90 1:10 2110 Temperture (°C) FIG. 1b 0.01 as:22“.Km: 217 095 24221.4 39Jmum/Q -0.8 35 155 255 255 Temperture (°C) Patent Application Publication Aug.
    [Show full text]
  • Horizon Scanning Status Report June 2019
    Statement of Funding and Purpose This report incorporates data collected during implementation of the Patient-Centered Outcomes Research Institute (PCORI) Health Care Horizon Scanning System, operated by ECRI Institute under contract to PCORI, Washington, DC (Contract No. MSA-HORIZSCAN-ECRI-ENG- 2018.7.12). The findings and conclusions in this document are those of the authors, who are responsible for its content. No statement in this report should be construed as an official position of PCORI. An intervention that potentially meets inclusion criteria might not appear in this report simply because the horizon scanning system has not yet detected it or it does not yet meet inclusion criteria outlined in the PCORI Health Care Horizon Scanning System: Horizon Scanning Protocol and Operations Manual. Inclusion or absence of interventions in the horizon scanning reports will change over time as new information is collected; therefore, inclusion or absence should not be construed as either an endorsement or rejection of specific interventions. A representative from PCORI served as a contracting officer’s technical representative and provided input during the implementation of the horizon scanning system. PCORI does not directly participate in horizon scanning or assessing leads or topics and did not provide opinions regarding potential impact of interventions. Financial Disclosure Statement None of the individuals compiling this information have any affiliations or financial involvement that conflicts with the material presented in this report. Public Domain Notice This document is in the public domain and may be used and reprinted without special permission. Citation of the source is appreciated. All statements, findings, and conclusions in this publication are solely those of the authors and do not necessarily represent the views of the Patient-Centered Outcomes Research Institute (PCORI) or its Board of Governors.
    [Show full text]
  • W W W .Bio Visio N .Co M New Products Added in 2020
    New products added in 2020 Please find below a list of all the products added to our portfolio in the year 2020. Assay Kits Product Name Cat. No. Size Product Name Cat. No. Size N-Acetylcysteine Assay Kit (F) K2044 100 assays Human GAPDH Activity Assay Kit II K2047 100 assays Adeno-Associated Virus qPCR Quantification Kit K1473 100 Rxns Human GAPDH Inhibitor Screening Kit (C) K2043 100 assays 20 Preps, Adenovirus Purification Kit K1459 Hydroxyurea Colorimetric Assay Kit K2046 100 assays 100 Preps Iodide Colorimetric Assay Kit K2037 100 assays Aldehyde Dehydrogenase 2 Inhibitor Screening Kit (F) K2011 100 assays Laccase Activity Assay Kit (C) K2038 100 assays Aldehyde Dehydrogenase 3A1 Inhibitor Screening Kit (F) K2060 100 assays 20 Preps, Lentivirus and Retrovirus Purification Kit K1458 Alkaline Phosphatase Staining Kit K2035 50 assays 100 Preps Alpha-Mannosidase Activity Assay Kit (F) K2041 100 assays Instant Lentivirus Detection Card K1470 10 tests, 20 tests Beta-Mannosidase Activity Assay Kit (F) K2045 100 assays Lentivirus qPCR Quantification Kit K1471 100 Rxns 50 Preps, Buccal Swab DNA Purification Kit K1466 Maleimide Activated KLH-Peptide Conjugation Kit K2039 5 columns 250 Preps Methionine Adenosyltransferase Activity Assay Kit (C) K2033 100 assays CD38 Activity Assay Kit (F) K2042 100 assays miRNA Extraction Kit K1456 50 Preps EZCell™ CFDA SE Cell Tracer Kit K2057 200 assays MMP-13 Inhibitor Screening Kit (F) K2067 100 assays Choline Oxidase Activity Assay Kit (F) K2052 100 assays Mycoplasma PCR Detection Kit K1476 100 Rxns Coronavirus
    [Show full text]
  • Stems for Nonproprietary Drug Names
    USAN STEM LIST STEM DEFINITION EXAMPLES -abine (see -arabine, -citabine) -ac anti-inflammatory agents (acetic acid derivatives) bromfenac dexpemedolac -acetam (see -racetam) -adol or analgesics (mixed opiate receptor agonists/ tazadolene -adol- antagonists) spiradolene levonantradol -adox antibacterials (quinoline dioxide derivatives) carbadox -afenone antiarrhythmics (propafenone derivatives) alprafenone diprafenonex -afil PDE5 inhibitors tadalafil -aj- antiarrhythmics (ajmaline derivatives) lorajmine -aldrate antacid aluminum salts magaldrate -algron alpha1 - and alpha2 - adrenoreceptor agonists dabuzalgron -alol combined alpha and beta blockers labetalol medroxalol -amidis antimyloidotics tafamidis -amivir (see -vir) -ampa ionotropic non-NMDA glutamate receptors (AMPA and/or KA receptors) subgroup: -ampanel antagonists becampanel -ampator modulators forampator -anib angiogenesis inhibitors pegaptanib cediranib 1 subgroup: -siranib siRNA bevasiranib -andr- androgens nandrolone -anserin serotonin 5-HT2 receptor antagonists altanserin tropanserin adatanserin -antel anthelmintics (undefined group) carbantel subgroup: -quantel 2-deoxoparaherquamide A derivatives derquantel -antrone antineoplastics; anthraquinone derivatives pixantrone -apsel P-selectin antagonists torapsel -arabine antineoplastics (arabinofuranosyl derivatives) fazarabine fludarabine aril-, -aril, -aril- antiviral (arildone derivatives) pleconaril arildone fosarilate -arit antirheumatics (lobenzarit type) lobenzarit clobuzarit -arol anticoagulants (dicumarol type) dicumarol
    [Show full text]
  • In Vivo Effect of PC-SPES on Prostate Growth and Hepatic CYP3A Expression in Rats
    JPET Fast Forward. Published on April 3, 2003 as DOI: 10.1124/jpet.102.048645 JPETThis Fast article Forward. has not been Published copyedited and on formatted. April 3, The 2003 final asversion DOI:10.1124/jpet.102.048645 may differ from this version. JPET #48645 In Vivo Effect of PC-SPES on Prostate Growth and Hepatic CYP3A Expression in Rats Teri Wadsworth, Hataya Poonyagariyagorn, Elinore Sullivan, Dennis Koop and Charles E. Roselli. Downloaded from Department of Physiology and Pharmacology Oregon Health & Science University, Portland, OR. jpet.aspetjournals.org at ASPET Journals on September 26, 2021 1 Copyright 2003 by the American Society for Pharmacology and Experimental Therapeutics. JPET Fast Forward. Published on April 3, 2003 as DOI: 10.1124/jpet.102.048645 This article has not been copyedited and formatted. The final version may differ from this version. JPET #48645 Running Title: In vivo effects of PC-SPES Correspondence: Dr. Charles E. Roselli, Department of Physiology and Pharmacology L334, Oregon Health Sciences University, 3181 SW Sam Jackson Park Road, Portland, OR 97201-3098, Tel (503) 494-5837, FAX (503) 494-4352, email: [email protected] Number of text pages: 20 number of tables: 4 Downloaded from number of figures: 4 number of references: 40 jpet.aspetjournals.org number of words in the Abstract: 250 number of words the Introduction: 748 number of words in the Discussion: 1478 at ASPET Journals on September 26, 2021 nonstandard abbreviations: National Institute of Diabetes and Digestive and Kidney Disease (NIDDK);
    [Show full text]